Pfizer’s Prevnar 13 Meets Phase III Endpoints

Pfizer announced that its Phase 3 immunogenicity and safety trials of Prevnar 13 in adults aged 50 years and older have met all study endpoints.

Pfizer announced that two Phase III immunogenicity and safety trials of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) have met all study endpoints in adults aged 50 years and older.

Data from both studies showed that Prevnar 13 was as immunogenic as the currently licensed nonconjugated pneumococcal polysaccharide vaccine (PPSV) for the 12 serotypes common to both vaccines in the age groups studied who were either pneumococcal vaccine-na?ve or previously immunized with PPSV. Also, the secondary endpoint data from both studies showed that Prevnar 13 had a statistically significant higher functional antibody response than PPSV against a majority of serotypes common to both vaccines and serotype 6A, a serotype not contained in PPSV.

<